SGLT-2 Therapy Center

SGLT inhibitors have changed the treatment landscape for cardiovascular and kidney disease, particularly in people with type 2 diabetes, heart failure, and chronic kidney disease. That success raises an obvious question: why are SGLT inhibitors in type 1 diabetes still largely outside routine clinical practice? The answer is not a …

Precision diabetes treatment aims to answer a question clinicians and patients face every day: which diabetes drug is most likely to work best for this particular person? A new analysis from the TriMaster crossover trial offers an important clue. Researchers compared several precision-medicine strategies for predicting responses to sitagliptin, canagliflozin, …

For people with diabetes, an unexpected glucose spike may have a less obvious cause than food or missed medication. Dehydration and high blood sugar can create a self-reinforcing cycle. When the body loses too much fluid, glucose becomes more concentrated in the bloodstream. At the same time, rising glucose can …

Euglycemic diabetic ketoacidosis can challenge one of the most familiar clinical shortcuts in diabetes care: DKA should come with markedly elevated glucose. In patients taking sodium-glucose cotransporter 2 (SGLT2) inhibitors, however, dangerous ketoacidosis may develop while glucose remains normal or only modestly elevated. As a result, euglycemic DKA in patients …

When a person develops diabetes at a young age, is not overweight, and has several family members with the condition, is it really type 2 diabetes? In many cases, the answer may be no. A growing body of evidence suggests that thousands of people worldwide are living with HNF1A-MODY, a …

For many people living with type 2 diabetes, the biggest challenge is not finding an effective medication. It is being able to afford it. That reality may begin to change now that the U.S. Food and Drug Administration (FDA) has approved the first generic versions of Farxiga (dapagliflozin), potentially making …

For years, the treatment of diabetic kidney disease focused primarily on glycemic control and blood pressure management. More recently, SGLT2 inhibitors and GLP-1 receptor agonists have transformed the landscape by reducing kidney disease progression and cardiovascular events. However, another therapeutic class is rapidly gaining recognition. Non-steroidal mineralocorticoid receptor antagonists (MRAs) …

Young adults diagnosed with type 2 diabetes early in life often face a more aggressive disease course than older adults. While metformin has long served as the standard first-line therapy, many clinicians are now reconsidering whether a “metformin-first and wait” strategy is enough for this higher-risk population. As research continues …

Discover how SGLT-2 inhibitors are transforming diabetes care and enhancing cardiovascular health, offering a multifaceted approach to treatment.

SGLT-2 inhibitors are a class of drugs that are used to treat type 2 diabetes. They work by blocking the reabsorption of glucose in the kidneys, allowing glucose to be excreted in the urine. As a result, they can help to reduce blood glucose levels and improve glycemic control. In …